Department of Urology, Osaka Medical and Pharmaceutical University, Osaka 569-8686, Japan.
Division of Urology, Department of Surgery, Brigham and Women's Hospital, Harvard Medical School, Boston, MA 02115, USA.
Int J Mol Sci. 2021 Nov 26;22(23):12777. doi: 10.3390/ijms222312777.
Prostate cancer (PCa) is one of the common malignancies in male adults. Recent advances in omics technology, especially in next-generation sequencing, have increased the opportunity to identify genes that correlate with cancer diseases, including PCa. In addition, a genetic screen based on CRISPR/Cas9 technology has elucidated the mechanisms of cancer progression and drug resistance, which in turn has enabled the discovery of new targets as potential genes for new therapeutic targets. In the era of precision medicine, such knowledge is crucial for clinicians in their decision-making regarding patient treatment. In this review, we focus on how CRISPR screen for PCa performed to date has contributed to the identification of biologically critical and clinically relevant target genes.
前列腺癌(PCa)是成年男性常见的恶性肿瘤之一。组学技术的最新进展,尤其是下一代测序技术,为识别与癌症相关的基因提供了更多机会,包括 PCa。此外,基于 CRISPR/Cas9 技术的遗传筛选阐明了癌症进展和耐药性的机制,这反过来又使新的治疗靶点成为新的潜在靶基因的发现成为可能。在精准医学时代,这些知识对于临床医生在患者治疗决策中至关重要。在这篇综述中,我们重点介绍迄今为止,CRISPR 筛选在识别具有生物学意义和临床相关性的靶基因方面的作用。